Cargando…
Recent Advances in the Pharmacology of Tardive Dyskinesia
Tardive dyskinesia (TD) is a syndrome of abnormal involuntary movements that follows treatment with dopamine D2-receptor antagonists. Recent approval of vesicular monoamine transporter-2 (VMAT2) inhibitors offers hope for reducing the impact of TD. Although these drugs represent a significant advanc...
Autor principal: | Caroff, Stanley N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean College of Neuropsychopharmacology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609206/ https://www.ncbi.nlm.nih.gov/pubmed/33124584 http://dx.doi.org/10.9758/cpn.2020.18.4.493 |
Ejemplares similares
-
Overcoming barriers to effective management of tardive dyskinesia
por: Caroff, Stanley N
Publicado: (2019) -
An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia
por: Ayyagari, Rajeev, et al.
Publicado: (2022) -
Effect of Varenicline on Tardive Dyskinesia: A Pilot Study
por: Caroff, Stanley N., et al.
Publicado: (2021) -
Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia
por: Caroff, Stanley N., et al.
Publicado: (2018) -
METOCLOPRAMIDE IN TARDIVE DYSKINESIA
por: Hemanani, T.J., et al.
Publicado: (1983)